Company profile: Synthon
1.1 - Company Overview
Company description
- Provider of affordable generic medicines and pharmaceutical development and manufacturing services, including API development, formulation development (solid oral dose, immediate and modified release, injectables), high-containment compounds for cancer treatment, R&D across multiple countries, and global manufacturing of tablets, capsules, and injectables.
Products and services
- Generic Medicines: Engineers, develops, and commercializes generic drug products across various therapeutic areas in a multi-therapeutic portfolio, coupling development with manufacturing to expand global access
- Manufacturing: Produces tablets, capsules, and injectables at its global facilities, constructing finished pharmaceutical products for commercialization with global-scale operations spanning dosage forms and therapeutic categories
- Formulation Development: Creates drug product formulations emphasizing solid oral dose, immediate-release, modified-release, injectables, and other dosage forms, offering multi-dosage-form development to support API and drug product advancement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Synthon
Telesta Therapeutics
HQ: Canada
Website
- Description: Provider of transformative human therapeutics, focused on licensing, acquisition, development, manufacturing and commercialization of novel medicines addressing major unmet medical needs, particularly in oncology; anchor product MCNA has completed a Phase III pivotal study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Telesta Therapeutics company profile →
Valo Therapeutics
HQ: Finland
Website
- Description: Provider of immuno-oncology platforms developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. Offerings include PeptiCRAd (oncolytic adenoviruses plus tumor-specific peptides), PeptiENV (oncolytic enveloped viruses with peptides), PeptiVAX (peptide-based cancer vaccines), PeptiBAC (bacteria delivering tumor peptides), and PeptiCHIP (microchip-based tumor neoantigen identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valo Therapeutics company profile →
Celyad Oncology
HQ: Belgium
Website
- Description: Provider of cell therapy treatments for severe diseases in immuno-oncology and cardiology, developing CAR T-cell technologies and medical devices. Offers a multispecific CAR approach targeting NKG2D ligands plus another target to address resistance and immune escape, and shRNA multiplexing for non-gene edited CAR T cells. Pipeline includes CAR-T NKR-2, C-Cure, and CYAD-01/02/03.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Celyad Oncology company profile →
ADC Therapeutics
HQ: Switzerland
Website
- Description: Provider of targeted oncology therapies, developing antibody-drug conjugates and non-ADC products for hematological cancers and solid tumors using proprietary PBD-dimer technology. Offerings include ZYNLONTA (CD19 ADC), the LOTIS clinical trial program, ADCT-602 (CD22 ADC for acute lymphoblastic leukemia), Mipasetamab uzoptirine/ADCT-601 (AXL-targeting), PBD-dimer technology, and support for investigator-initiated trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ADC Therapeutics company profile →
Calypso Biotech
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical research and development focused on therapeutics for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calypso Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Synthon
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Synthon
2.2 - Growth funds investing in similar companies to Synthon
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Synthon
4.2 - Public trading comparable groups for Synthon
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →